A Phase 2a, Multi-Center, Randomized, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ACE-011 (hActRIIA-IgG1) in Patients With Osteolytic Lesions of Multiple Myeloma.

Next Previous
Trial Profile

A Phase 2a, Multi-Center, Randomized, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ACE-011 (hActRIIA-IgG1) in Patients With Osteolytic Lesions of Multiple Myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2014

At a glance

  • Drugs Sotatercept (Primary) ; Melphalan; Prednisolone; Thalidomide
  • Indications Cancer metastases; Multiple myeloma
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Celgene Corporation

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 12 Mar 2010 Celgene Corporation added as trial sponsor as reported by ClinicalTrials.gov.
    • 11 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top